- Home
- MAGH vs ANL Comparison
MAGH vs ANL Comparison
Compare MAGH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGH
- ANL
- Stock Information
- Founded
- MAGH 2012
- ANL 2004
- Country
- MAGH Singapore
- ANL Cayman Islands
- Employees
- MAGH N/A
- ANL N/A
- Industry
- MAGH Engineering & Construction
- ANL
- Sector
- MAGH Industrials
- ANL
- Exchange
- MAGH Nasdaq
- ANL Nasdaq
- Market Cap
- MAGH 51.8M
- ANL 61.8M
- IPO Year
- MAGH 2025
- ANL 2023
- Fundamental
- Price
- MAGH $1.67
- ANL $1.51
- Analyst Decision
- MAGH
- ANL Hold
- Analyst Count
- MAGH 0
- ANL 1
- Target Price
- MAGH N/A
- ANL N/A
- AVG Volume (30 Days)
- MAGH 210.5K
- ANL 6.5K
- Earning Date
- MAGH 11-08-2025
- ANL 11-11-2025
- Dividend Yield
- MAGH N/A
- ANL N/A
- EPS Growth
- MAGH N/A
- ANL N/A
- EPS
- MAGH 0.00
- ANL N/A
- Revenue
- MAGH $11,752,129.00
- ANL N/A
- Revenue This Year
- MAGH N/A
- ANL N/A
- Revenue Next Year
- MAGH N/A
- ANL N/A
- P/E Ratio
- MAGH $1,777.24
- ANL N/A
- Revenue Growth
- MAGH N/A
- ANL N/A
- 52 Week Low
- MAGH $0.99
- ANL $1.10
- 52 Week High
- MAGH $5.15
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- MAGH N/A
- ANL 34.86
- Support Level
- MAGH N/A
- ANL $1.55
- Resistance Level
- MAGH N/A
- ANL $1.67
- Average True Range (ATR)
- MAGH 0.00
- ANL 0.09
- MACD
- MAGH 0.00
- ANL -0.02
- Stochastic Oscillator
- MAGH 0.00
- ANL 12.00
About MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.